Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable...

Details Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable... Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable...

2006-08-31

2011-12-06

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253110, C514S254010, C514S252130, C540S523000, C540S524000, C540S575000, C544S052000, C544S092000, C544S105000, C544S121000, C544S287000, C544S295000, C544S357000, C544S361000, C544S362000, C544S363000, C544S364000, C544S366000, C544S367000, C544S368000, C544S369000, C544S370000, C544S371000, C544S372000, C544S373000, C544S376000

Reexamination Certificate

active

08071600

ABSTRACT:
A heterocyclic compound or a salt thereof represented by the formula (1): where R2represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R1represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

REFERENCES:
patent: 4234584 (1980-11-01), Lattrell et al.
patent: 4831031 (1989-05-01), Lowe, III et al.
patent: 4883795 (1989-11-01), Lowe, III et al.
patent: 2003/0050306 (2003-03-01), Ruhland et al.
patent: 2003/0195219 (2003-10-01), Dutta
patent: 0 367 141 (1990-05-01), None
patent: 0 512 525 (1992-11-01), None
patent: 0 732 332 (1996-09-01), None
patent: 0 934 932 (1999-08-01), None
patent: 1 188 747 (2002-03-01), None
patent: 2 740 134 (1997-04-01), None
patent: 2 761 068 (1998-09-01), None
patent: 56-49361 (1981-05-01), None
patent: WO 91/00863 (1991-01-01), None
patent: WO 96/22290 (1996-07-01), None
patent: WO 98/07703 (1998-02-01), None
patent: WO 00/71517 (2000-11-01), None
patent: WO 02/066469 (2002-08-01), None
patent: WO 2004/026864 (2004-04-01), None
patent: WO 2004/029048 (2004-04-01), None
patent: WO 2005/019215 (2005-03-01), None
Yagcioglu, Turkish Journal of Psychiatry, vol. 18(4), p. 1-10 (2007).
Aripiprazole, from Wikipedia, 1 page, retrieved from the Internet at http://en.wikipedia.org/wiki/Aripiprazole on Feb. 1, 2011.
Tramontina et al. J.Clin.Psychiatry, vol. 70(5),pp. 756-764 (2009) (Abstract provided).
M. Toru, “Creativity in the Development of the Drug, Aripiprazole: A Novel Partial Dopamine D2Receptor Agonist for the Treatment of Schizophrenia”, Seishin-Igaku, Psychiatry, vol. 46, pp. 855-864, (2004).
Harrison et al., “Aripiprazole: A Review of Its Use in Schizophrenia and Schizoaffective Disorder”, ADIS Drug Evaluation, Drugs, vol. 64, No. 15, pp. 1715-1736, (2004).
Pullar et al., “LY367265, An Inhibitor of the 5-Hydroxytryptamine Transporter and 5-Hydroxytryptamine2AReceptor Antagonist : A Comparison With the Antidepressant, Nefazodone”, European Journal of Pharmacology, vol. 407, pp. 39-46, (2000).
Meltzer et al, “Serotonin Receptors : Their Key Role in Drugs to Treat Schizophrenia”, Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, pp. 1159-1172, (2003).
Svensson, “α-Adrenoceptor Modulation Hypothesis of Antipsychotic Atypicality”, Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, pp. 1145-1158, (2003).
Oshiro et al., “Novel Antipsychotic Agents With Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-Piperazinyl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone Derivatives”, J. Med. Chem., vol. 41, pp. 658-667, (1998).
Ishigooka et al., “Trends in the Clinical Development of the Second Generation Antipsychotics”, Rinsho-Seishin-Yakuri, Japanese Journal of Clinical Psychopharmacology), vol. 4, pp. 1653-1644, (2001).
Findling et al., “Aripiprazole in Children with Attention-Deficit/Hyperactivity Disorder,”J. Child&Adolesc. Psychopharmacol., 18(4):347-54 (2008).
Keck et al., “A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients with Bipolar I Disorder,”J. Clin. Psychiatry, 67(4):626-37 (2006).
Marcus et al., “A Double-Blind, Randomized, Placebo-Controlled Study of Fixed-Dose Aripiprazole in Children and Adolescents with Autistic Disorder,”J. Am. Acad. Child Adolesc. Psychiatry, 48(11):1110-19 (2009).
Partial translation of Murasaki et al., “The Prospect of New Pharmacological Treatment Against Psychiatric Disorders”, Rinsho-Seishin-Yakuri, (Japanese Journal of Clinical Psychopharmacology), 1:5-22 (1998).
Translation of Kikuchi et al., “Aripiprazole, A Novel Antipsychotic—A Dopamine D2Partial Agonist”, Nou-no-Kagaku, Brain Science, 25:579-583 (2003).
English language abstract of FR 2 740134 A1, (1997).
Search Report and Written Opinion for Singapore Patent Application No. 200905174-9 dated Aug. 3, 2010.
English language Derwent abstract of FR 2 761 068 A1, (1998).

Affiliated with

Also associated with

Rating

Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4294637